Anonymous
Guest
Anonymous
Guest
I don't work in LRL but if it's anything like sales and the bogus things we put on our DAPs every year, that could be the problem. It may sound like this. 1. Develop 40 molecules to be put thru phase 1 development. This is to achieve the needs of shareholders and Wall Street, nothing really having to do with new development of innovative molecules. Just something JL can brag about..... We have 250 molecules in phase 1, when everyone knows that nothing will ever come of any of them. What Lilly really needs is TRUE innovation. If we can't do it internally because our lame PM process then we need to change it NOW but in the mean time go outside Lilly and work with a lab that has something innovative in phase 3, that is TRULY innovative and almost a sure thing in getting FDA approval! At the same time lets spin off a subsidiary that manufacturers generics!!!
I am a chemist. I don't work for Lilly and would not work for Lilly.
But I can tell you that you are correct about this statistical mumbo-jumbo hocus-pocus.
You want to see real medicinal chemistry? Look at what they do in France or Russia. There is just no comparison to Lilly. Never. Never in 150 years has Lilly ever come even close. You people are just too conservative. Sorry.